Stock 6446 PHARMAESSENTIA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaEssentia Corporation

Equities

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
285.5 TWD -1.04% Intraday chart for PharmaEssentia Corporation 0.00% -17.49%
Apr. 26 PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA CI
Apr. 24 PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 24,120 24,709 78,065 143,840 114,578 94,759 - -
Enterprise Value (EV) 1 22,809 21,664 75,148 133,629 94,995 77,213 76,270 78,695
P/E ratio -28.6 x -11.7 x -27.1 x -98.6 x -179 x 41.6 x 17.6 x -
Yield - - - - - - 0.57% -
Capitalization / Revenue 78.9 x 44.3 x 119 x 49.9 x 22.4 x 11.3 x 7.64 x 6.23 x
EV / Revenue 74.6 x 38.9 x 114 x 46.4 x 18.6 x 9.2 x 6.15 x 5.17 x
EV / EBITDA -32 x -14.1 x -29 x -74.2 x -57.8 x 182 x 31.4 x 15.1 x
EV / FCF -21.4 x -14.1 x -29.7 x -73.5 x -49.8 x -105 x 42.9 x -
FCF Yield -4.67% -7.09% -3.37% -1.36% -2.01% -0.95% 2.33% -
Price to Book 11 x 6.3 x 19.1 x 11.2 x 4.79 x 3.63 x 3.19 x 3.19 x
Nbr of stocks (in thousands) 219,277 263,418 266,434 301,552 331,149 331,905 - -
Reference price 2 110.0 93.80 293.0 477.0 346.0 285.5 285.5 285.5
Announcement Date 2/26/20 3/3/21 3/2/22 3/1/23 2/27/24 - - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 305.7 557.3 656.5 2,882 5,106 8,390 12,407 15,222
EBITDA 1 -711.8 -1,541 -2,595 -1,800 -1,645 425.3 2,428 5,212
EBIT 1 -849.2 -1,716 -2,822 -2,028 -1,913 544.9 3,120 4,567
Operating Margin -277.8% -307.91% -429.91% -70.37% -37.48% 6.49% 25.15% 30%
Earnings before Tax (EBT) 1 -842.1 -1,948 -2,811 -1,842 -986.9 2,051 6,048 -
Net income 1 -843 -1,948 -2,811 -1,375 -623.8 2,051 4,839 -
Net margin -275.77% -349.59% -428.17% -47.7% -12.22% 24.45% 39% -
EPS 2 -3.850 -8.040 -10.80 -4.840 -1.930 6.870 16.21 -
Free Cash Flow 1 -1,066 -1,536 -2,532 -1,818 -1,906 -735 1,778 -
FCF margin -348.64% -275.72% -385.74% -63.06% -37.33% -8.76% 14.33% -
FCF Conversion (EBITDA) - - - - - - 73.24% -
FCF Conversion (Net income) - - - - - - 36.74% -
Dividend per Share 2 - - - - - - 1.620 -
Announcement Date 2/26/20 3/3/21 3/2/22 3/1/23 2/27/24 - - -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 92.06 380 251.7 977.7 810.8 841.7 887.6 1,265 1,306 1,647 1,781 2,322 2,083 2,943
EBITDA -647.5 -891 -490.7 -270.5 -510.5 - - -348.9 -585.6 - - - - -
EBIT 1 -703.3 -951.9 -557 -326.6 -564.9 -579.7 -725.5 -404.8 -645 -132.1 3 183 93 864
Operating Margin -763.89% -250.5% -221.24% -33.4% -69.67% -68.88% -81.73% -32.01% -49.38% -8.02% 0.17% 7.88% 4.46% 29.36%
Earnings before Tax (EBT) 1 -700.3 -886.8 -540.9 -274.7 -408.8 -617.5 -760 -203.1 190.9 -214.7 238 410 320 1,091
Net income 1 -700.3 -886.8 -540.9 -274.7 -408.8 -150.4 -735.5 -202.8 198.5 115.9 230 410 320 1,091
Net margin -760.72% -233.37% -214.84% -28.1% -50.42% -17.87% -82.86% -16.03% 15.2% 7.04% 12.91% 17.66% 15.36% 37.07%
EPS 2 -2.700 -3.390 -1.960 -0.9800 -1.440 -0.4700 -2.440 -0.6200 0.6600 0.3800 0.7700 1.370 1.070 3.650
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/2/22 5/16/22 8/12/22 11/14/22 3/1/23 5/11/23 8/10/23 11/9/23 2/27/24 - - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,312 3,045 2,917 10,211 19,582 17,546 18,489 16,064
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -1,066 -1,536 -2,532 -1,818 -1,906 -735 1,778 -
ROE (net income / shareholders' equity) -35.7% -63.1% -68.8% -16.8% -3.46% 4.53% 13.4% 14.6%
ROA (Net income/ Total Assets) -29.2% -45.9% -47.9% -12.8% -2.93% 4.02% 11.1% 14.4%
Assets 1 2,882 4,245 5,865 10,765 21,301 51,001 43,403 -
Book Value Per Share 2 10.00 14.90 15.30 42.70 72.30 78.60 89.50 89.50
Cash Flow per Share 2 -4.310 -6.010 -9.460 - -2.190 2.200 7.360 14.10
Capex 1 121 81.2 70.3 312 1,200 1,549 2,846 -
Capex / Sales 39.49% 14.56% 10.71% 10.83% 23.51% 18.46% 22.94% -
Announcement Date 2/26/20 3/3/21 3/2/22 3/1/23 2/27/24 - - -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PharmaEssentia Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
285.5 TWD
Average target price
417.2 TWD
Spread / Average Target
+46.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
-17.49% 2.9B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6446 Stock
  4. Financials PharmaEssentia Corporation